Initially wary of releasing their clinical trial data, many drug companies have made the information available to researchers. But Pfizer Inc.’s Craig Lipset says firms need to do more to get the data into the public sphere.
Speaking at FasterCures’ Partnering for Cures conference in New York Nov. 17, Lipset, head of clinical innovation for Pfizer worldwide...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?